Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.46 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | FNTA | P49354 | 2/20 | 0.37 |
| ▸ | FNTB | P49356 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7678067 | 0.88 | CXCL8 (0.41) | CYP1A2MAPTCYP2C9L3MBTL1PTGS2 | |
| SCHEMBL7678263 | 0.86 | TSHR (0.42) | MAPTCYP2D6CYP2C19ALDH1A1KMT2A | |
| SCHEMBL7675675 | 0.85 | HTT (0.42) | HTTCYP1A2MAPTCYP2C9CYP2D6 | |
| SCHEMBL7674662 | 0.85 | HTT (0.39) | HTTCYP1A2MAPTCYP2C9CYP2D6 | |
| SCHEMBL7678781 | 0.85 | HTT (0.46) | HTTMAPTCYP2C9L3MBTL1NPSR1 | |
| SCHEMBL7678575 | 0.84 | MAPT (0.41) | HTTMAPTL3MBTL1FNTAFNTB | |
| SCHEMBL7677941 | 0.84 | SMN1; SMN2 (0.49) | HTTCYP1A2MAPTCYP2C9CYP2C19 | |
| SCHEMBL7680382 | 0.84 | ALDH1A1 (0.38) | MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL7684736 | 0.75 | ATM (0.34) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL7675515 | 0.74 | ALDH1A1 (0.35) | CYP1A2MAPTCYP2C19L3MBTL1FNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6455703-B2 | ADMINISTERING EFFECTIVE AMOUNT OF 1,3,6-TRIHYDRO-6-AZA-3-OXAPENTALEN-2-ONE DERIVATIVE TO THE PATIENT FOR INDUCING OR PROMOTING APOPTOSIS AND FOR ARRESTING UNCONTROLLED NEOPLASTIC CELL PROLIFERATION | CELL PATHWAYS, INC. | 2002-09-24 | — | — | US | disclosed |
| US-20010051651-A1 | 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | OSI PHARMACEUTICALS, INC. | 2001-12-13 | — | — | US | disclosed |
| US-6160003-A | 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | CELL PATHWAYS, INC. (US) | 2000-12-12 | — | — | US | disclosed |
| US-5939417-A | 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | CELL PATHWAYS INC (US) | 1999-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051651-A1 | 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | MALT1, VHL, CDKN1A | HTT 2603/4885P2RX4 4180/4885CYP1A2 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.